

## **POSITION PSYHOTROPIC ANTIDEPRESSANTS ON PHARMACEUTICAL MARKET OF KAZAKHSTAN**

L.R. Ablayeva, A.R. Shopabaeva, S.V. Khimenko.

S.D. Asfendiyarov National University of Medicine in Kazakhstan, Almaty,

The Republic of Kazakhstan

The National Pharmaceutical University, Kharkov, Ukraine

email: Lenykaro@mail.ru

Relevance of the topic. in the total burden of disease in the Republic of Kazakhstan a special place occupy mental illness and their percentage is growing every year, today corresponds 1,9%. Relevance of marketing research pharmaceutical market of psychotropic antidepressants is in constant growth in the Republic of Kazakhstan some socially significant diseases including mental. Especially, frequently reported persistent neurotic disorders and psychosomatic pathology.

Goal research: an analysis of psychotropic antidepressants in the pharmaceutical market of the Republic of Kazakhstan (RK)

Research methods: content analysis, factorial cluster analysis. Analysis of the official scientific literature, qualitative and quantitative market research.

Results and conclusions: found that the share of the pharmaceutical market of the Republic of Kazakhstan for the 2013 year (turnover on public procurement) psychotropic antidepressants compose 0.01%. Moreover, psychotropic antidepressants include 23 trade names of drugs, exclusively foreign production in the absence of domestic medicines. Preferable dosage forms are tablets - 58.8, capsules - 41.2%. Conclusion: pharmaceutical market revealed a very low proportion and limited range of antidepressants in the structure of general assortment of drugs Republic of Kazakhstan. National production of the studied drugs not mastered.